

Ultrasound contrast agents may help identify uterine disorders and prostate cancers.

September 09, 2024 09:52 AM Eastern Daylight Time

CHICAGO--([BUSINESS WIRE](#))--Ultrasound contrast agents show promise for detecting and evaluating uterine disorders and prostate cancers, scientists reported today at the annual Advances in Contrast Ultrasound conference in Chicago.

Ultrasound contrast agents are generally used to evaluate tumors and organ systems throughout the body, including the heart, liver, kidneys and bowel, according to the International Contrast Ultrasound Society.

Studies of uterine disorders extend the team's prior work using ultrasound contrast agents and CUDI to detect and evaluate prostate cancer.

This work focuses on angiogenesis, the growth of micro blood vessels towards and through a tumor in response to the tumor's need for more oxygen and nutrients, according to Dr. Hessel Wijkstra, who also is a professor of signal processing at Eindhoven University of Technology and spoke at the conference.

"This technology is relatively cheap, automated and not operator dependent," he said in a presentation at the conference.